Reozalimab
Based on 1 Customer Validation
Reozalimab (LY3434172; IBI-318) is an IgG1 monoclonal antibody targeting PD-1/PD-L1, with an IC50 of 2.27 nM and an EC50 of 0.080 nM against human PD-1, as well as an IC50 of 0.75 nM and an EC50 of 0.455 nM against human PD-L1. Reozalimab blocks the binding of PD-1 to PD-L1/PD-L2, as well as the binding of PD-L1 to PD-1/CD80, thereby inhibiting the inhibitory signal transduction of the PD-1 pathway. Reozalimab enhances the functional activation of T cells and induces anti-tumor activity in mouse tumor models reconstituted with human immune cells. Reozalimab can be used in research related to cancers such as non-small cell lung cancer and ovarian cancer.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity : 99.90%
- CAS No.: 2445259-99-2
- 분자량:143.55 kDa
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- 순도&문서
- References
-
Help & FAQs
-
HY-P9902
PembrolizumabPD-1 Inhibitor -
HY-P9904
AtezolizumabAnti-PD-L1 Antibody -
HY-P9971
CamrelizumabPD-1 Neutralizing Antibody -
HY-P9903
NivolumabPD-1 Inhibitor -
HY-P9919
DurvalumabPD-L1 Blocking Antibody -
HY-P99052
TislelizumabPD-1 Inhibitor -
HY-P9978
ToripalimabPD-1 Inhibitor -
HY-108730
AvelumabAnti-PD-L1 Antibody -
HY-P99048
SintilimabPD-1/PD-L1 Inhibitor -
HY-P9919A
Durvalumab (anti-PD-L1)PD-1/PD-L1 Inhibitor -
HY-P99203
CemiplimabPD-1 Inhibitor -
HY-P99118
SerplulimabAnti-PD-1 Antibody
Biological Activity
제품 설명
Isotype
Ig(G1-kappa_G1-lambda2)
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
PDCD1 & CD274
In Vitro
Reozalimab (1 h) blocks the interactions of PD-1/PD-L2 and PD-L1/CD80, with corresponding IC50 values of 2.27 nM and 0.75 nM, respectively, and also inhibits the binding of PD-1/PD-L1[2].
Reozalimab binds to human and cynomolgus monkey PD-1 and PD-L1 with high affinity, but does not bind to mouse or rat PD-1 or PD-L1[2].
Reozalimab (1 h) specifically binds to CHO-K1 cells expressing PD-1 and PD-L1, with corresponding EC50 values of 2.39 nM and 0.589 nM[2].
Reozalimab (6 h) enhances T cell activation in the co-culture system of CHO-K1 cells expressing PD-L1 or co-expressing PD-L1+PD-L2 with NFAT-luc2/PD1 Jurkat cells, with EC50 values of 0.12 nM and 0.18 nM, respectively[2].
Reozalimab (66 h) enhances the activation of naive human CD4 T cells in allogeneic MLR, with an EC50 of 0.01 nM[2].
Reozalimab enhances primary human pan-T cell-mediated killing of HEL 92.1.7 tumor cells, with an EC50 of 0.005 nM[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Parmacokinetics
| Species | Dose | Route | CL | T1/2 | Vss |
|---|---|---|---|---|---|
| Mice[2] | 10 mg/kg | i.v. | 0.15 | 293 | 68.1 mL/kg |
In Vivo
Reozalimab (0.0025-0.25 mg/kg; i.p.; once weekly) exhibits significant anti-tumor activity in the prophylactic NCI-H292 NSCLC humanized mouse model[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:NOD/SCID Gamma (NSG) (female, 7 weeks of age)[2]
-
Dosage:2 mg/kg; 0.2 mg/kg; 0.02 mg/kg
-
Administration:i.p.; once weekly
-
Result:Achieved a %T/C of 3.9 at 2 mg/kg/wk.
Achieved a %T/C of 19.4 at 0.2 mg/kg/wk.
Achieved a %T/C of 50.3 at 0.02 mg/kg/wk.
Caused no significant body weight changes across all doses.
-
Animal Model:NOD/SCID Gamma (NSG) (female, 7 weeks of age)[2]
-
Dosage:0.25 mg/kg; 0.025 mg/kg; 0.0025 mg/kg
-
Administration:i.p.; once weekly
-
Result:Achieved a %T/C of 6 with 5/8 complete responders (CRs) at 0.25 mg/kg/wk.
Induced 1/8 CRs at 0.025 mg/kg/wk with %T/C not specified.
Induced 0/8 CRs at 0.0025 mg/kg/wk with %T/C not specified.
Was significantly more efficacious than anti-PD-L1 monotherapy and the combination of anti-PD-1 and anti-PD-L1.
Caused no significant body weight changes across all doses.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Ig(G1-kappa_G1-lambda2)
신청
ELISA, FACS, Functional assay
Chemical Information
-
CAS No. 2445259-99-2
-
Appearance Liquid
-
분자량 143.55 kDa
-
Color Colorless to light yellow
-
SMILES
[Reozalimab]
-
Synonyms
LY3434172; IBI-318
-
선적
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
순도&문서
-
Data Sheet (262 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Reozalimab Related Classifications
HY-P9996 Related Classifications
Powered by Bioz